Do paraneoplastic neurologic antibodies only matter when cancer is active?

Paraneoplastic neurologic antibody results are clinically meaningful only in context. In a 77-year-old man, a positive result should trigger careful phenotype- and antibody-directed assessment, rather than being treated as proof of either active cancer or cancer recurrence.

Timing and cancer surveillance

• Antibodies and neurologic autoimmunity may precede cancer detection. In a 295-patient anti-Hu cohort, delayed cancers diagnosed more than 2 years after presentation had a median 30-month interval from antibody detection to cancer diagnosis.
• Antibody-associated neurologic disease may also accompany cancer: most cancers in that cohort were identified within 2 years of neurologic onset.
• After cancer treatment, onconeural antibodies commonly remain detectable despite tumor response or neurologic stabilization. Persistent seropositivity alone does not establish residual cancer, relapse, or treatment failure; serial antibody titers should not direct treatment.
• For high-risk antibody/phenotype presentations with initially negative screening, guidance supports repeat targeted cancer evaluation every 4–6 months for 2 years.

Diagnostic interpretation and mechanisms

• PNS-Care classification depends on convergence of a validated antibody, characteristic neurologic syndrome, compatible tumor, and cancer status. A compatible tumor markedly strengthens the inference that the immune response is paraneoplastic; an atypical tumor requires evidence of the relevant tumor antigen.
• Antibody specificity is important: anti-Hu, Yo, Ri, CRMP5, amphiphysin, and Ma2 are high-risk onconeural antibodies, but expected neurologic phenotypes and tumor associations differ. For example, Yo is associated with breast/gynecologic cancer, and CRMP5 with small-cell lung cancer or thymoma.
• Commercial line-blot results require orthogonal confirmation with tissue-based and antigen-specific assays. In one large assessment, only 30–37% of commercial positives were confirmed, varying from 6–7% for Yo to 65–88% for Hu.

Bottom line

• The claim is well supported: antibodies can precede, coincide with, or persist after cancer, but their significance rests on validated testing plus antibody–syndrome–tumor concordance and the evolving evidence for active malignancy.